Neil Murphy1, Howard D Strickler2, Frank Z Stanczyk2, Xiaonan Xue2, Sylvia Wassertheil-Smoller2, Thomas E Rohan2, Gloria Y F Ho2, Garnet L Anderson2, John D Potter2, Marc J Gunter2. 1. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK (NM, MJG); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, NY (HDS, XX, SWS, TER, GYFH); Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California, Los Angeles, CA (FZS); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA, JDP); Centre for Public Health Research, Massey University, Wellington, New Zealand (JDP). neil.murphy@imperial.ac.uk. 2. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK (NM, MJG); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, NY (HDS, XX, SWS, TER, GYFH); Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California, Los Angeles, CA (FZS); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA, JDP); Centre for Public Health Research, Massey University, Wellington, New Zealand (JDP).
Abstract
BACKGROUND: Postmenopausal hormone therapy use has been associated with lower colorectal cancer risk in observational studies. However, the role of endogenous sex hormones in colorectal cancer development in postmenopausal women is uncertain. METHODS: The relation of colorectal cancer risk with circulating levels of estradiol, estrone, free (bioactive) estradiol, progesterone and sex hormone-binding globulin (SHBG) was determined in a nested case-control study of 1203 postmenopausal women (401 case patients and 802 age and race/ethnicity-matched control patients) enrolled in the Women's Health Initiative Clinical Trial (WHI-CT) who were not assigned to the estrogen-alone or combined estrogen plus progestin intervention groups. We used multivariable-adjusted conditional logistic regression models that included established colorectal cancer risk factors. All statistical tests were two-sided. RESULTS: Comparing extreme quartiles, estrone (odds ratio [OR]q4-q1 = 0.44, 95% confidence interval [CI] = 0.28 to 0.68, P trend = .001), free estradiol (ORq4-q1 = 0.43, 95% CI = 0.27 to 0.69, P trend ≤ .0001), and total estradiol (ORq4-q1 = 0.58, 95% CI = 0.38 to 0.90, P trend = .08) were inversely associated with colorectal cancer risk. SHBG levels were positively associated with colorectal cancer development (OR[q4-q1] = 2.30, 95% CI = 1.51 to 3.51, P trend ≤ .0001); this association strengthened after further adjustment for estradiol and estrone (ORq4-q1 = 2.50, 95% CI = 1.59 to 3.92, P trend < .0001). Progesterone was not associated with colorectal cancer risk. CONCLUSION: Endogenous estrogen levels were inversely, and SHBG levels positively, associated with colorectal cancer risk, even after control for several colorectal cancer risk factors. These results suggest that endogenous estrogens may confer protection against colorectal tumorigenesis among postmenopausal women.
BACKGROUND: Postmenopausal hormone therapy use has been associated with lower colorectal cancer risk in observational studies. However, the role of endogenous sex hormones in colorectal cancer development in postmenopausal women is uncertain. METHODS: The relation of colorectal cancer risk with circulating levels of estradiol, estrone, free (bioactive) estradiol, progesterone and sex hormone-binding globulin (SHBG) was determined in a nested case-control study of 1203 postmenopausal women (401 case patients and 802 age and race/ethnicity-matched control patients) enrolled in the Women's Health Initiative Clinical Trial (WHI-CT) who were not assigned to the estrogen-alone or combined estrogen plus progestin intervention groups. We used multivariable-adjusted conditional logistic regression models that included established colorectal cancer risk factors. All statistical tests were two-sided. RESULTS: Comparing extreme quartiles, estrone (odds ratio [OR]q4-q1 = 0.44, 95% confidence interval [CI] = 0.28 to 0.68, P trend = .001), free estradiol (ORq4-q1 = 0.43, 95% CI = 0.27 to 0.69, P trend ≤ .0001), and total estradiol (ORq4-q1 = 0.58, 95% CI = 0.38 to 0.90, P trend = .08) were inversely associated with colorectal cancer risk. SHBG levels were positively associated with colorectal cancer development (OR[q4-q1] = 2.30, 95% CI = 1.51 to 3.51, P trend ≤ .0001); this association strengthened after further adjustment for estradiol and estrone (ORq4-q1 = 2.50, 95% CI = 1.59 to 3.92, P trend < .0001). Progesterone was not associated with colorectal cancer risk. CONCLUSION: Endogenous estrogen levels were inversely, and SHBG levels positively, associated with colorectal cancer risk, even after control for several colorectal cancer risk factors. These results suggest that endogenous estrogens may confer protection against colorectal tumorigenesis among postmenopausal women.
Authors: N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson Journal: Endocr Relat Cancer Date: 1999-06 Impact factor: 5.678
Authors: Michael S Simon; Rowan T Chlebowski; Jean Wactawski-Wende; Karen C Johnson; Andrew Muskovitz; Ikuko Kato; Alicia Young; F Allan Hubbell; Ross L Prentice Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Jill R Johnson; James V Lacey; Deann Lazovich; Melissa A Geller; Catherine Schairer; Arthur Schatzkin; Andrew Flood Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Tess V Clendenen; Karen L Koenig; Roy E Shore; Mortimer Levitz; Alan A Arslan; Anne Zeleniuch-Jacquotte Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Joshua Petimar; Stephanie A Smith-Warner; Bernard Rosner; Andrew T Chan; Edward L Giovannucci; Fred K Tabung Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-24 Impact factor: 4.254
Authors: Kristin Wallace; Allan DeToma; David N Lewin; Shaoli Sun; Don Rockey; Carolyn D Britten; Jennifer D Wu; Aissatou Ba; Anthony J Alberg; Elizabeth G Hill Journal: Clin Colorectal Cancer Date: 2016-12-07 Impact factor: 4.481
Authors: Song-Yi Park; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson; Loïc Le Marchand Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396
Authors: Mingyang Song; Walter C Willett; Frank B Hu; Donna Spiegelman; Aviva Must; Kana Wu; Andrew T Chan; Edward L Giovannucci Journal: Int J Cancer Date: 2016-02-08 Impact factor: 7.396
Authors: Wanshui Yang; Edward L Giovannucci; Susan E Hankinson; Andrew T Chan; Yanan Ma; Kana Wu; Charles S Fuchs; I-Min Lee; Howard D Sesso; Jennifer H Lin; Xuehong Zhang Journal: Int J Cancer Date: 2020-01-11 Impact factor: 7.396
Authors: Neil Murphy; Robert Carreras-Torres; Mingyang Song; Andrew T Chan; Richard M Martin; Nikos Papadimitriou; Niki Dimou; Konstantinos K Tsilidis; Barbara Banbury; Kathryn E Bradbury; Jelena Besevic; Sabina Rinaldi; Elio Riboli; Amanda J Cross; Ruth C Travis; Claudia Agnoli; Demetrius Albanes; Sonja I Berndt; Stéphane Bézieau; D Timothy Bishop; Hermann Brenner; Daniel D Buchanan; N Charlotte Onland-Moret; Andrea Burnett-Hartman; Peter T Campbell; Graham Casey; Sergi Castellví-Bel; Jenny Chang-Claude; María-Dolores Chirlaque; Albert de la Chapelle; Dallas English; Jane C Figueiredo; Steven J Gallinger; Graham G Giles; Stephen B Gruber; Andrea Gsur; Jochen Hampe; Heather Hampel; Tabitha A Harrison; Michael Hoffmeister; Li Hsu; Wen-Yi Huang; Jeroen R Huyghe; Mark A Jenkins; Temitope O Keku; Tilman Kühn; Sun-Seog Kweon; Loic Le Marchand; Christopher I Li; Li Li; Annika Lindblom; Vicente Martín; Roger L Milne; Victor Moreno; Polly A Newcomb; Kenneth Offit; Shuji Ogino; Jennifer Ose; Vittorio Perduca; Amanda I Phipps; Elizabeth A Platz; John D Potter; Conghui Qu; Gad Rennert; Lori C Sakoda; Clemens Schafmayer; Robert E Schoen; Martha L Slattery; Catherine M Tangen; Cornelia M Ulrich; Franzel J B van Duijnhoven; Bethany Van Guelpen; Kala Visvanathan; Pavel Vodicka; Ludmila Vodickova; Veronika Vymetalkova; Hansong Wang; Emily White; Alicja Wolk; Michael O Woods; Anna H Wu; Wei Zheng; Ulrike Peters; Marc J Gunter Journal: Gastroenterology Date: 2019-12-27 Impact factor: 22.682